Results 1 to 10 of about 695,469 (357)

SARS-CoV-2 reinfection in interstitial lung disease patients and its association with clinical deterioration: a two-year prospective cohort study [PDF]

BMC Infectious Diseases
Background The COVID-19 pandemic has raised concerns about respiratory sequelae, particularly in the patients with preexisting interstitial lung disease (ILD).
Yuanying Wang, Dongmei Wang, Yawen Song, Na Wu, Xuqin Du, Qiao Ye   +5 more
doaj   +2 more sources

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review

International Journal of Molecular Sciences, 2023
Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide.
F. Amati, Anna Stainer, Veronica Polelli, M. Mantero, A. Gramegna, F. Blasi, S. Aliberti   +6 more
semanticscholar   +1 more source

Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis

Respiratory Research, 2022
Background Advanced pulmonary sarcoidosis causes significant morbidity and can lead to death. Large trials demonstrated efficacy of antifibrotics in patients with progressive fibrosing interstitial lung diseases (PF-ILD), including a few with sarcoidosis.
M. C. Schimmelpennink, D. B. Meek, A. D. M. Vorselaars, L. C. M. Langezaal, C. H. M. van Moorsel, J. J. van der Vis, M. Veltkamp, J. C. Grutters   +7 more
doaj   +1 more source

Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers

International Journal of Molecular Sciences, 2023
Connective tissue disease-associated interstitial lung disease (CTD-ILD) is a collection of systemic autoimmune disorders resulting in lung interstitial abnormalities or lung fibrosis.
G. Cerro Chiang, T. Parimon
semanticscholar   +1 more source

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial

Arthritis & Rheumatology, 2022
To analyze the efficacy and safety of nintedanib in patients with fibrosing autoimmune disease–related interstitial lung diseases (ILDs) with a progressive phenotype.
E. Matteson, C. Kelly, J. Distler, A. Hoffmann-Vold, J. Seibold, S. Mittoo, P. Dellaripa, M. Aringer, J. Pope, O. Distler, A. James, R. Schlenker‐Herceg, S. Stowasser, M. Quaresma, K. Flaherty   +14 more
semanticscholar   +1 more source

Decreased Survival and Lung Function in Progressive Pulmonary Fibrosis

Medicina, 2023
Background and Objectives: Progressive pulmonary fibrosis (PPF) is a recently described term reserved for patients with fibrotic ILD other than idiopathic pulmonary fibrosis (IPF) with fast clinical deterioration. Here, survival and prognostic biomarkers
Mark G. J. P. Platenburg, Joanne J. van der Vis, Jan C. Grutters, Coline H. M. van Moorsel   +3 more
doaj   +1 more source

Comprehensive Analysis of Fibroblast Activation Protein Expression in Interstitial Lung Diseases

American Journal of Respiratory and Critical Care Medicine, 2022
Rationale Sustained activation of lung fibroblasts and the resulting oversynthesis of the extracellular matrix are detrimental events for patients with interstitial lung diseases (ILDs).
Penghui Yang, Q. Luo, Xinlu Wang, Qi Fang, Z. Fu, Jia Li, Y. Lai, Xiao-bo Chen, Xin Xu, Xiaomin Peng, Kongzhen Hu, X. Nie, Shaoyu Liu, Jinhe Zhang, Junqi Li, C. Shen, Ying-ying Gu, Jianping Liu, Jingyu Chen, N. Zhong, Jin Su   +20 more
semanticscholar   +1 more source

Clustering of lung diseases in the family of interstitial lung disease patients

BMC Pulmonary Medicine, 2022
Background The presence of familial interstitial lung disease (ILD) has been found to predict development of progressive pulmonary fibrosis. However, the role of non-ILD lung diseases in ILD patients’ families has not yet been investigated.
Michelle Terwiel, Jan C. Grutters, Coline H. M. van Moorsel   +2 more
doaj   +1 more source

No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis

ERJ Open Research, 2023
Background Telomere dysfunction can underly the development of idiopathic pulmonary fibrosis (IPF), and recent work suggests that patients with telomere syndromes might benefit from treatment with androgens, such as danazol.
Thijs W. Hoffman, Coline H.M. van Moorsel, Joanne J. van der Vis, Douwe H. Biesma, Jan C. Grutters   +4 more
doaj   +1 more source

Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms

International Journal of Molecular Sciences, 2021
Interstitial lung diseases (ILDs) comprise different fibrotic lung disorders characterized by cellular proliferation, interstitial inflammation, and fibrosis.
P. Montero, J. Milara, I. Roger, J. Cortijo   +3 more
semanticscholar   +1 more source